ICD-10-CM Billable Code

K12.31

Oral mucositis (ulcerative) due to antineoplastic therapy

Clinical Classification Guidelines

Use Additional Code

  • code for adverse effect, if applicable, to identify antineoplastic and immunosuppressive drugs (T45.1X5)

Medical Intelligence & Overview

Oral mucositis, particularly the ulcerative type caused by antineoplastic therapy, is a common side effect experienced by many cancer patients undergoing treatment. This condition involves inflammation and the development of painful ulcers within the mucous membranes of the mouth. Recognizing its symptoms, causes, and available management options can help in maintaining oral health during treatment.

Causes & Symptoms

Clinical Causes: Use of antineoplastic agents such as chemotherapy drugs Radiation therapy directed at head and neck areas Pre-existing oral health issues that may exacerbate mucositis Poor oral hygiene practices during cancer treatment Concurrent infections or immune suppression

Key Symptoms: Pain or soreness in the mouth and throat Presence of ulcers or sores on the mucous membranes Redness and inflammation of the oral tissues Difficulty swallowing or eating due to discomfort Dry mouth or increased saliva production Bleeding from oral ulcers Increased risk of secondary infections in the oral cavity

Diagnostic & Treatment

Diagnosis Path: Diagnosis is primarily clinical, based on a thorough examination of the mouth and review of the patient's medical history. Healthcare professionals look for characteristic ulcers, inflammation, and other oral changes, especially in patients undergoing or who have recently undergone cancer treatments. Additional assessment may include microbial cultures if secondary infection is suspected.

Treatment Protocols: Management of oral mucositis due to antineoplastic therapy focuses on alleviating symptoms, promoting healing, and preventing complications. Common approaches include: - Maintaining meticulous oral hygiene to minimize infection risk - Using mouth rinses such as saline or prescribed solutions to soothe the mucosa - Applying topical anesthetics to reduce pain - Using prescribed medications that promote tissue healing - Adjusting or temporarily halting cancer therapy if necessary and safe - Ensuring adequate hydration and nutrition - Implementing pain management strategies as advised by healthcare providers In some cases, specialized supportive treatments like low-level laser therapy or growth factors may be recommended. Preventive measures include pre-treatment oral assessments and counseling on oral care routines.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is K12.31 a billable ICD-10 code?
Yes, K12.31 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report K12.31?
Clinical documentation must specify the nature of Oral mucositis (ulcerative) due to antineoplastic therapy and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Related Diagnosis Codes

Clinical Meta Tags

antineoplastic therapy mucositis